|
|
| Line 1: |
Line 1: |
| __NOTOC__
| | #REDIRECT [[Doxazosin#Adverse Reactions]] |
| {{Doxazosin}}
| |
| {{CMG}}; {{AE}} {{AK}}
| |
| | |
| ==Adverse Reactions==
| |
| | |
| ===A. Benign Prostatic Hyperplasia (BPH)===
| |
| | |
| The incidence of adverse events has been ascertained from worldwide clinical trials in 965 BPH patients. The incidence rates presented below (Table 3) are based on combined data from seven placebo-controlled trials involving once-daily administration of doxazosin in doses of 1 to 16 mg in hypertensives and 0.5 to 8 mg in normotensives. The adverse events when the incidence in the doxazosin group was at least 1% are summarized in Table 3. No significant difference in the incidence of adverse events compared to placebo was seen except for dizziness, [[fatigue]], [[hypotension]], edema, and dyspnea. [[Dizziness ]]and [[dyspnea ]]appeared to be dose-related.
| |
| {|
| |
| |[[image:doxa5.png|600px|thumb]]
| |
| |}
| |
| In these placebo-controlled studies of 665 doxazosin patients treated for a mean of 85 days, additional adverse reactions have been reported. These are less than 1% and not distinguishable from those that occurred in the placebo group. Adverse reactions with an incidence of less than 1% but of clinical interest are (doxazosin vs. placebo): Cardiovascular System: [[angina pectoris]] (0.6% vs. 0.7%), [[postural hypotension]] (0.3% vs. 0.3%), [[syncope ]](0.5% vs. 0.0%), [[tachycardia ]](0.9% vs. 0.0%); Urogenital System: [[dysuria ]](0.5% vs. 1.3%); and Psychiatric Disorders: [[libido ]]decreased (0.8% vs. 0.3%). The safety profile in patients treated for up to three years was similar to that in the placebo-controlled studies.
| |
| | |
| The majority of adverse experiences with doxazosin were mild.
| |
| | |
| ===B. Hypertension===
| |
| | |
| Doxazosin has been administered to approximately 4000 hypertensive patients, of whom 1679 were included in the hypertension clinical development program. In that program, minor adverse effects were frequent, but led to discontinuation of treatment in only 7% of patients. In placebo-controlled studies, adverse effects occurred in 49% and 40% of patients in the doxazosin and placebo groups, respectively, and led to discontinuation in 2% of patients in each group. The major reasons for discontinuation were postural effects (2%), edema, [[malaise]]/[[fatigue]], and some heart rate disturbance, each about 0.7%.
| |
| | |
| In controlled hypertension clinical trials directly comparing doxazosin to placebo, there was no significant difference in the incidence of side effects, except for dizziness (including postural), weight gain, [[somnolence]], and fatigue/malaise. Postural effects and edema appeared to be dose-related. The prevalence rates presented below are based on combined data from placebo-controlled studies involving once-daily administration of doxazosin at doses ranging from 1 to 16 mg. Table 4 summarizes those adverse experiences (possibly/probably related) reported for patients in these [[hypertension ]]studies where the prevalence rate in the doxazosin group was at least 0.5% or where the reaction is of particular interest.
| |
| {|
| |
| |[[image:doxa6.png|600px|thumb]]
| |
| |}
| |
| Additional adverse reactions have been reported, but these are, in general, not distinguishable from symptoms that might have occurred in the absence of exposure to doxazosin. The following adverse reactions occurred with a frequency of between 0.5% and 1%: [[syncope]], [[hypoesthesia]], increased [[sweating]], [[agitation]], increased weight. The following additional adverse reactions were reported by <0.5% of 3960 patients who received doxazosin in controlled or open, short- or long-term clinical studies, including international studies. Cardiovascular System: [[angina pectoris]], [[myocardial infarction]], cerebrovascular accident; Autonomic Nervous System: [[pallor]]; Metabolic: thirst, [[gout]], [[hypokalemia]]; Hematopoietic: [[lymphadenopathy]], [[purpura]]; Reproductive System: breast pain; Skin Disorders: [[alopecia]], dry skin, [[eczema]]; Central Nervous System: [[paresis]], [[tremor]], [[twitching]], [[confusion]], [[migraine]], impaired concentration; Psychiatric: [[paroniria]], [[amnesia]], emotional lability, abnormal thinking, depersonalization; Special Senses:[[parosmia]], [[earache]], taste perversion, [[photophobia]], abnormal [[lacrimation]]; Gastrointestinal System: increased appetite, [[anorexia]], fecal [[incontinence]], gastroenteritis; Respiratory System: [[bronchospasm]], [[sinusitis]], [[coughing]], [[pharyngitis]]; Urinary System: renal [[calculus]]; General Body System:[[ hot flushes]], [[back pain]], infection, fever/rigors, decreased weight, influenza-like symptoms.
| |
| | |
| Doxazosin has not been associated with any clinically significant changes in routine biochemical tests. No clinically relevant adverse effects were noted on serum potassium, serum [[glucose]], [[uric acid]],[[ blood urea nitrogen]], [[creatinine ]]or liver function tests. Doxazosin has been associated with decreases in white blood cell counts (see[[Doxazosin precautions|PRECAUTIONS, Leukopenia/Neutropenia]]).
| |
| | |
| In post-marketing experience, the following additional adverse reactions have been reported: Autonomic Nervous System: [[priapism]]; Central Nervous System: [[hypoesthesia]];Endocrine System: [[gynecomastia]]; Gastrointestinal System: [[vomiting]]; General Body System: allergic reaction; Heart Rate/Rhythm: [[bradycardia]]; Hematopoietic: [[leukopenia]], [[thrombocytopenia]]; Liver/Biliary System: [[hepatitis]], hepatitis cholestatic; Respiratory System: [[bronchospasm ]]aggravated; Skin Disorders: [[urticaria]]; Special Senses: Intraoperative Floppy Iris Syndrome (see [[Doxazosin precautions|PRECAUTIONS, Cataract Surgery]]); Urinary System: [[hematuria]], [[micturition ]]disorder, [[micturition ]]frequency, [[nocturia]].<ref name="dailymed.nlm.nih.gov">{{Cite web | last = | first = | title = DOXAZOSIN TABLET [APOTEX CORP.] | url = http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=4fa5c2f7-cda9-56cd-622f-b3d05dc7c94b | publisher = | date = | accessdate = 7 March 2014 }}</ref>
| |
| | |
| | |
| | |
| | |
| ==References==
| |
| | |
| {{Reflist|2}}
| |
| | |
| [[Category:Cardiovascular Drugs]]
| |
| [[Category:Drugs]]
| |